reMYND licenses highly innovative transgenic mouse models of Alzheimer's Disease TAU and Amyloid pathology from the University of Leuven. Visit the University of Leuven website
reMYND licenses highly innovative transgenic mouse models
reMYND installs world-class scientific advisory board
reMYND installs world-class scientific advisory board with Parkinson's and Alzheimer's Disease experts.
Lead product for treating Parkinson's Disease demonstrates efficacy
Lead product for treating Parkinson's Disease demonstrates efficacy in 3 different animal models of Parkinson's Disease: a chemically-induced model and 2 different transgenic α-synuclein mouse models.
reMYND signs license agreement
reMYND signs a license agreement with another biotech company for their internal use of reMYND’s proprietary APPLon model.
reMYND's Parkinson's disease drug discovery program reaches breakthrough
Press release | reMYND nv announced today that it has reached a breakthrough in its drug discovery program aimed at identifying disease-modifying drugs for the treatment of Parkinson's disease.